Status:
TERMINATED
LMWH to Prevent Preeclampsia and Fetal Growth Restriction
Lead Sponsor:
University of Florence
Conditions:
Preeclampsia
Eligibility:
FEMALE
20-40 years
Brief Summary
The objective of this trial will be to determine whether prophylactic low-molecular weight heparin therapy in pregnant women with the heterozygous Factor V Leiden and G20210A prothrombin gene mutation...
Detailed Description
The objective of this trial will be to determine whether prophylactic low-molecular weight heparin therapy in pregnant women with the heterozygous Factor V Leiden and G20210A prothrombin gene mutation...
Eligibility Criteria
Inclusion
- Previous severe preeclampsia
- Previous severe fetal growth restriction
- Heterozygous Factor V Leiden
- Heterozygous G20210A prothrombin gene mutations
Exclusion
- renal disease
- chronic hypertension
- preexisting diabetes mellitus
- homozygosity for Factor V Leiden
- homozygosity for prothrombin G20210A mutation
- hyperhomocysteinemia
- protein C deficency
- protein S deficency
- antithrombin deficiency
- positive anticardiolipin antibodies
- positive lupus anticoagulant
Key Trial Info
Start Date :
January 1 2002
Trial Type :
OBSERVATIONAL
End Date :
December 1 2003
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00260520
Start Date
January 1 2002
End Date
December 1 2003
Last Update
March 6 2006
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.